N/A N=700 Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ
Major Depressive Disorder
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 80; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=294 S&P of Q-Fix™ All-Suture Anchor System
Bankart Lesion · Acetabular Labrum Tear · SLAP Lesion
Primary: Clinical Success Rate, Defined as Participant Joints Without Reintervention at 6 Months Post-operative, as Assessed by the Surgeon — 306 joints
Phase 2 N=23 A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
Stable Schizophrenia
Primary: Change From Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Second Testing After TAK-041 Administration — 29.72; 27.35; 27.89…
Phase 2 N=213 A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics
Schizophrenia
Primary: Change From Baseline to Week 24 in MATRICS Consensus Cognitive Battery (MCCB) Neurocognitive Composite Score — 32.50; 32.36; -0.17; -0.28 Composite T-Score — p=0.730
Phase 2 N=69 Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
Head and Neck Neoplasms
Primary: Percentage of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) — 12.5 Percentage of participants
Phase 4 N=70 A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane
HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Primary: Severity of Adverse Events — 53; 40; 18; 2 Participants
Phase 2 N=15 Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction
Liver Transplant Recipient · Living Donor (of the Respective Liver Transplant Recipient)
Primary: Number of Participants Who Experienced Grade 3 or Higher Adverse Events (AEs) Deemed Attributable to darTreg Infusion — 0 Participants
N/A N=110 ENgaging in Advance Care Planning Talks Group Visit Intervention
Advance Care Planning · Primary Health Care
Primary: Presence of Medical Decision-maker Documentation in the EHR — 41; 38; 51; 40 participants
Phase 1 N=68 Safety and Pharmacokinetic Study of Y242 in Adult Subjects
Obesity
Primary: Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) — 0; 3; 6; 6 Participants
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Phase 2 N=22 Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
Uveitis · Macular Edema · Uveitis, Posterior
Primary: Change From Baseline in Central Subfield Thickness, Measured Using Optical Coherence Tomography, After Treatment With CLS-TA in Subjects With Macular Edema Following…
N/A N=100 VectorFlow Tunneled Dialysis Catheter (TDC) Versus Palindrome TDC
Renal Failure Chronic Requiring Hemodialysis · Chronic Renal Insufficiency
Primary: Primary Patency - Intervention-free Interval (Measured in Weeks) — 89.1; 95.5; 79.4; 87.2 percentage of primary patency
Phase 4 N=41 Vortioxetine for Posttraumatic Stress Disorder
Post-Traumatic Stress Disorder
Primary: Change Clinician Administered PTSD Scale Score — 16; 17 score on a scale
N/A N=150 Risk Identification of the GlucoTab System in Routine Use
Diabetes Mellitus
Primary: Efficacy: Blood Glucose During Hospital Stay, an Expected Average of 1 Week — 159 mg/dl
Phase 2 N=28 Esmolol vs. Labetalol in Endoscopic Sinus Surgery
Chronic Sinusitis
Primary: Intra-operative Surgical Visibility - Boezaart Scale — 3.1; 3.1 score on a scale